This is the first study giving evidence that the described putative tumor suppressive function of NDRG2 may be confined to luminal- or basal B-type breast tumors: A more frequently retained NDRG2 mRNA expression associated with unfavorable clinical outcome in basal-type breast cancer patients. This evidence concerns the gene NDRG2 and breast carcinoma.